<DOC>
	<DOCNO>NCT01565018</DOCNO>
	<brief_summary>To investigate compare drug amount deliver body single administration Rotigotine patch 2 different formulation healthy Japanese subject .</brief_summary>
	<brief_title>Bioequivalence Study Rotigotine Transdermal Patch With Two Different Formulations Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>N 0437</mesh_term>
	<criteria>Healthy Japanese male female volunteer age 20 55 year old Subject participate participate clinical study investigational drug another Investigational Medical Product ( IMP ) within last 3 month Subject healthy ( eg , take drug treatment , excessive amount alcohol , cigarette , medical emotional/psychological problem , drug/alcohol abuse , abnormal safety parameter ) Subject QTcB ( QT interval correct Heart Rate [ HR ] use Bazett´s formula ) interval ≥ 430 m ( ≥ 450 m female ) clinically relevant find Electrocardiogram ( ECG ) Eligibility Assessment ( EA ) Subject clinically relevant allergy clinically relevant drug hypersensitivity component Investigational Medical Product ( IMP ) , or/and atopic eczematous Dermatitis , Psoriasis and/or active skin disease Subject recent history ( within 2 year ) chronic alcohol drug abuse history significant skin hypersensitivity transdermal product , atopic eczematous Dermatitis , Psoriasis , and/or active skin disease history suicide attempt , Epilepsy and/or seizure Subject make blood donation comparable blood loss within last 3 month prior Eligibility Assessment ( EA ) Subject pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Transdermal Patch</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>